Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design Public Deposited

Downloadable Content

Download PDF
Creator
  • Do, Thy P
    • Other Affiliation: Amgen, Inc, Thousand Oaks, CA, USA
  • Kshirsagar, Abhijit
    • Affiliation: School of Medicine, Department of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center
  • Reams, B. D
    • Affiliation: Cecil G. Sheps Center for Health Services Research
  • Bradbury, Brian D
    • Other Affiliation: Amgen, Inc, Thousand Oaks, CA, USA
  • Dluzniewski, Paul J
    • Other Affiliation: Amgen, Inc, Thousand Oaks, CA, USA
  • Brookhart, M. Alan
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Yue, Susan V
    • Other Affiliation: Amgen, Inc, Thousand Oaks, CA, USA
Abstract
  • Abstract Background Cinacalcet is used to treat secondary hyperparathyroidism among hemodialysis patients. Large-scale epidemiologic studies describing patterns of cinacalcet use, effects on parathyroid hormone (PTH), calcium, and phosphorous levels, and predictors of discontinuation have not been previously reported. Methods This retrospective cohort study used a clinical database of a large U.S. dialysis provider (2007–2010) merged with administrative data from the United States Renal Data System. Among new users of cinacalcet with Medicare coverage, trends in PTH, calcium, and phosphorus were measured in 30-day intervals following cinacalcet initiation. Results Seventeen thousand seven hundred sixty-three eligible initiators contributed 111,047 30-day follow-up intervals. Of these, 56 % discontinued cinacalcet by month 4. Of those discontinuing, 76.3 % reinitiated. Mean values of PTH, calcium, and phosphorus decreased to recommended levels within 4 months following initiation. Proximal PTH levels <150 pg/mL were associated with discontinuation: HR = 1.23 (95 % CI: 1.12, 1.36), whereas low calcium (<7.5 mg/dL) was suggestive of an association, HR = 1.09 (95 % CI 0.91, 1.32). Being in the Part D gap period increased discontinuation risk: HR = 1.09 (95 % CI: 1.03, 1.16). Low-income subsidy status decreased discontinuation risk: HR = 0.77 (95 % CI 0.69, 0.86). Predictors of reinitiation included low-income subsidy, HR = 1.32 (95 % CI 1.22, 1.43); higher albumin level, HR = 1.23 (95 % CI 1.10, 1.36) and higher calcium level, HR = 1.26 (95 % CI 1.19, 1.33). Conclusions Substantial and expected declines in laboratory values occurred following cinacalcet initiation. Early discontinuation and reinitiation of cinacalcet were common and may have occurred for clinical and economic reasons.
Date of publication
Identifier
  • doi:10.1186/s12882-015-0174-6
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Reams et al.
Language
  • English
Bibliographic citation
  • BMC Nephrology. 2015 Oct 29;16(1):175
Publisher
  • BioMed Central
Parents:

This work has no parents.

Items